These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 25562773)

  • 1. Cost and consequences of noncompliance to oral bisphosphonate treatment.
    Eisenberg DF; Placzek H; Gu T; Krishna A; Tulsi BB
    J Manag Care Spec Pharm; 2015 Jan; 21(1):56-65. PubMed ID: 25562773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost and consequences of noncompliance with osteoporosis treatment among women initiating therapy.
    Modi A; Siris ES; Tang J; Sen S
    Curr Med Res Opin; 2015 Apr; 31(4):757-65. PubMed ID: 25661017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost and health care resource use associated with noncompliance with oral bisphosphonate therapy: an analysis using Danish health registries.
    Kjellberg J; Jorgensen AD; Vestergaard P; Ibsen R; Gerstoft F; Modi A
    Osteoporos Int; 2016 Dec; 27(12):3535-3541. PubMed ID: 27394414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost.
    Martin KE; Yu J; Campbell HE; Abarca J; White TJ
    J Manag Care Pharm; 2011 Oct; 17(8):596-609. PubMed ID: 21942301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistance and Compliance with Osteroporosis Therapies Among Women in a Commercially Insured Population in the United States.
    Cheng LI; Durden E; Limone B; Radbill L; Juneau PL; Spangler L; Mirza FM; Stolshek BS
    J Manag Care Spec Pharm; 2015 Sep; 21(9):824-33, 833a. PubMed ID: 26308229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between refill compliance to oral bisphosphonate treatment, incident fractures, and health care costs--an analysis using national health databases.
    Olsen KR; Hansen C; Abrahamsen B
    Osteoporos Int; 2013 Oct; 24(10):2639-47. PubMed ID: 23604250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medical utilization associated with palivizumab compliance in a commercial and managed medicaid health plan.
    Diehl JL; Daw JR; Coley KC; Rayburg R
    J Manag Care Pharm; 2010; 16(1):23-31. PubMed ID: 20044844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosis.
    Halpern R; Becker L; Iqbal SU; Kazis LE; Macarios D; Badamgarav E
    J Manag Care Pharm; 2011; 17(1):25-39. PubMed ID: 21204588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of compliance and persistence with bisphosphonate therapy on health care costs and utilization.
    Sunyecz JA; Mucha L; Baser O; Barr CE; Amonkar MM
    Osteoporos Int; 2008 Oct; 19(10):1421-9. PubMed ID: 18351427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association Between Gastrointestinal Events and Health Care Resource Utilization Among Patients with Osteoporosis: Analysis of a U.S. Managed Care Population.
    Modi A; Gold DT; Yang X; Fan CP; Sajjan SG
    J Manag Care Spec Pharm; 2015 Sep; 21(9):811-21. PubMed ID: 26308228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential clinical and economic impact of nonadherence with osteoporosis medications.
    Hiligsmann M; Rabenda V; Gathon HJ; Ethgen O; Reginster JY
    Calcif Tissue Int; 2010 Mar; 86(3):202-10. PubMed ID: 20205345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate: a population-based study.
    Blouin J; Dragomir A; Fredette M; Ste-Marie LG; Fernandes JC; Perreault S
    Osteoporos Int; 2009 Sep; 20(9):1571-81. PubMed ID: 19107385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between gastrointestinal events and persistence with osteoporosis therapy: analysis of administrative claims of a U.S. managed care population.
    Modi A; Siris S; Yang X; Fan CP; Sajjan S
    J Manag Care Spec Pharm; 2015 Jun; 21(6):499-506. PubMed ID: 26011551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of compliance with GOLD treatment recommendations on COPD health care resource utilization, cost, and exacerbations among patients with COPD on maintenance therapy.
    Palli SR; Zhou S; Shaikh A; Willey VJ
    J Manag Care Spec Pharm; 2021 May; 27(5):625-637. PubMed ID: 33779246
    [No Abstract]   [Full Text] [Related]  

  • 15. Compliance with drug therapies for the treatment and prevention of osteoporosis.
    McCombs JS; Thiebaud P; McLaughlin-Miley C; Shi J
    Maturitas; 2004 Jul; 48(3):271-87. PubMed ID: 15207894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship Between Gastrointestinal Events and Compliance With Osteoporosis Therapy: An Administrative Claims Analysis of the US Managed Care Population.
    Modi A; Sajjan S; Michael Lewiecki E; Harris ST; Papadopoulos Weaver J
    Clin Ther; 2016 May; 38(5):1074-80. PubMed ID: 27112533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
    Vogelzang NJ; Pal SK; Ghate SR; Li N; Swallow E; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
    J Manag Care Spec Pharm; 2018 Jun; 24(6):525-533. PubMed ID: 29799328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost-effectiveness of osteoporosis medications for preventing periprosthetic fractures following femoral neck fracture indicated hip arthroplasty: a break-even analysis.
    Agarwal AR; Kinnard MJ; Murdock C; Zhao AY; Ahiarakwe U; Cohen JS; Moseley KF; Golladay GJ; Thakkar SC
    Osteoporos Int; 2024 Jul; 35(7):1223-1229. PubMed ID: 38619605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of proton pump inhibitor compliance on health-care resource utilization and costs in patients with gastroesophageal reflux disease.
    Gosselin A; Luo R; Lohoues H; Toy E; Lewis B; Crawley J; Duh MS
    Value Health; 2009; 12(1):34-9. PubMed ID: 19895371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health Care Resource Utilization and Costs Among Newly Diagnosed and Oral Anticoagulant-Naive Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the United States.
    Jain R; Fu AC; Lim J; Wang C; Elder J; Sander SD; Tan H
    J Manag Care Spec Pharm; 2018 Jan; 24(1):73-82. PubMed ID: 29290177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.